| A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis F Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, ... Leukemia 31 (12), 2726-2731, 2017 | 350 | 2017 |
| Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial T Barbui, AM Vannucchi, V De Stefano, A Masciulli, A Carobbio, A Ferrari, ... The Lancet Haematology 8 (3), e175-e184, 2021 | 129 | 2021 |
| Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts F Passamonti, M Maffioli, F Cervantes, AM Vannucchi, E Morra, T Barbui, ... Blood, The Journal of the American Society of Hematology 123 (12), 1833-1835, 2014 | 118 | 2014 |
| A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis M Maffioli, B Mora, S Ball, A Iurlo, EM Elli, MC Finazzi, N Polverelli, ... Blood advances 6 (6), 1855-1864, 2022 | 84 | 2022 |
| Myelofibrosis F Passamonti, B Mora Blood 141 (16), 1954-1970, 2023 | 75 | 2023 |
| Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis N Gagelmann, F Passamonti, C Wolschke, R Massoud, C Niederwieser, ... Haematologica 107 (8), 1840, 2021 | 69 | 2021 |
| COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies F Passamonti, A Romano, M Salvini, F Merli, MGD Porta, R Bruna, ... British Journal of Haematology 195 (3), 371-377, 2021 | 67 | 2021 |
| Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study P Guglielmelli, A Ghirardi, A Carobbio, A Masciulli, C Maccari, B Mora, ... Blood Advances 6 (2), 373-375, 2022 | 59 | 2022 |
| Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients F Passamonti, B Mora, T Giorgino, P Guglielmelli, M Cazzola, M Maffioli, ... Leukemia 31 (4), 970-973, 2017 | 55 | 2017 |
| Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses PE Debureaux, B Cassinat, J Soret-Dulphy, B Mora, E Verger, N Maslah, ... Blood advances 4 (15), 3708-3715, 2020 | 40 | 2020 |
| Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project B Mora, T Giorgino, P Guglielmelli, E Rumi, M Maffioli, A Rambaldi, ... Haematologica 103 (9), e392, 2018 | 39 | 2018 |
| Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera T Barbui, AM Vannucchi, V De Stefano, A Carobbio, A Ghirardi, G Carioli, ... NEJM evidence 2 (6), EVIDoa2200335, 2023 | 37 | 2023 |
| New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms F Passamonti, B Mora, M Maffioli Current opinion in hematology 23 (2), 137-143, 2016 | 33 | 2016 |
| Looking for CALR mutations in familial myeloproliferative neoplasms M Maffioli, A Genoni, D Caramazza, B Mora, A Bussini, M Merli, ... Leukemia 28 (6), 1357-1360, 2014 | 33 | 2014 |
| Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients S Ruberti, E Bianchi, P Guglielmelli, S Rontauroli, G Barbieri, L Tavernari, ... Leukemia 32 (2), 438-449, 2018 | 32 | 2018 |
| Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches M Maffioli, B Mora, F Passamonti Clinical Advances in Hematology & Oncology 15 (9), 700-707, 2017 | 30 | 2017 |
| Post-ET and post-PV myelofibrosis: updates on a distinct prognosis from primary myelofibrosis F Passamonti, B Mora, D Barraco, M Maffioli Current hematologic malignancy reports 13, 173-182, 2018 | 28 | 2018 |
| Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients M Maffioli, T Giorgino, B Mora, A Iurlo, E Elli, MC Finazzi, M Caramella, ... Blood Advances 3 (21), 3196-3200, 2019 | 26 | 2019 |
| It is time to change thrombosis risk assessment for PV and ET? F Passamonti, D Caramazza, B Mora, R Casalone, M Maffioli Best Practice & Research Clinical Haematology 27 (2), 121-127, 2014 | 24 | 2014 |
| Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection M Merli, W Ageno, F Sessa, M Salvini, D Caramazza, B Mora, A Rossi, ... Annals of Hematology 99, 1951-1952, 2020 | 23 | 2020 |